The role of fluorine-18-fluorodeoxyglucose positron emission tomography in aggressive histological subtypes of thyroid cancer: An overview

International Journal of Endocrinology

Volumn 2013, Issue , 2013, Pages

  Treglia, Giorgio ^a   Annunziata, Salvatore ^b   Muoio, Barbara ^c   Salvatori, Massimo ^b   Ceriani, Luca ^a   Giovanella, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b CATHOLIC UNIVERSITY   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOACTIVE IODINE;

CANCER PROGNOSIS; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; METASTASIS; ONCOCYTOMA; POORLY DIFFERENTIATED THYROID CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; THYROID CANCER; THYROID CARCINOMA; THYROID SURGERY;

EID: 84877284512     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2013/856189     Document Type: Review

References (38)

1. Cooper D. S., Doherty G. M., Haugen B. R., Kloos R. T., Lee S. L., Mandel S. J., Mazzaferri E. L., McIver B., Pacini F., Schlumberger M., Sherman S. I., Steward D. L., Tuttle R. M., Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009 19 11 1167 1214 2-s2.0-70449370231 10.1089/thy.2009.0110
2. Kloos R. T., Eng C., Evans D. B., Francis G. L., Gagel R. F., Gharib H., Moley J. F., Pacini F., Ringel M. D., Schlumberger M., Wells S. A., Medullary thyroid cancer: management guidelines of the American thyroid association. Thyroid 2009 19 6 565 612 2-s2.0-67749130797
3. Smallridge R. C., Ain K. B., Asa S. L., Bible K. C., Brierley J. D., Burman K. D., Kebebew E., Lee N. Y., Nikiforov Y. E., Rosenthal M. S., Shah M. H., Shaha A. R., Tuttle R. M., American association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012 22 11 1104 1139 10.1089/thy.2012.0302
4. Grünwald F., Kälicke T., Feine U., Lietzenmayer R., Scheidhauer K., Dietlein M., Schober O., Lerch H., Brandt-Mainz K., Burchert W., Hiltermann G., Cremerius U., Biersack H. J., Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. European Journal of Nuclear Medicine 1999 26 12 1547 1552 2-s2.0-0033457279 10.1007/s002590050493 (Pubitemid 30010291)
5. Treglia G., Muoio B., Giovanella L., Salvatori M., The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. European Archives of Oto-Rhino-Laryngology 2012 10.1007/s00405-012-2205-2
6. Giovanella L., Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Expert Review of Endocrinology and Metabolism 2012 7 1 35 43 10.1586/eem.11.83
7. Giovanella L., Ceriani L., de Palma D., Suriano S., Castellani M., Verburg F. A., Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. Head and Neck 2012 34 5 626 631 10.1002/hed.21791
8. Feine U., Lietzenmayer R., Hanke J. P., Wohrle H., Muller-Schauenburg W., 18FDG whole-body PET in differentiated thyroid carcinoma. Flipflop in uptake patterns of 18FDG and 131I. NuklearMedizin 1995 34 4 127 134 2-s2.0-0029355220
9. Grabellus F., Nagarajah J., Bockisch A., Schmid K. W., Sheu S. Y., Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clinical Nuclear Medicine 2012 37 2 121 127 10.1097/RLU.0b013e3182393599
10. Hundahl S. A., Cady B., Cunningham M. P., Mazzaferri E., McKee R. F., Rosai J., Shah J. P., Fremgen A. M., Stewart A. K., Hölzer S., Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German thyroid cancer study group: an American college of surgeons commission on cancer patient care evaluation study. Cancer 2000 89 1 202 217 (Pubitemid 30451292)
11. Abraham T., Schöder H., Thyroid cancer-indications and opportunities for positron emission tomography/computed tomography imaging. Seminars in Nuclear Medicine 2011 41 2 121 138 2-s2.0-79251482826 10.1053/j.semnuclmed.2010. 10.006
12. Stojadinovic A., Ghossein R. A., Hoos A., Urist M. J., Spiro R. H., Shah J. P., Brennan M. F., Shaha A. R., Singh B., Hürthle cell carcinoma: a critical histopathologic appraisal. Journal of Clinical Oncology 2001 19 10 2616 2625 2-s2.0-0035873951 (Pubitemid 32441366)
13. Blount C. L., Dworkin H. J., F-18 FDG uptake by recurrent Hurthle cell carcinoma of the thyroid using high-energy planar scintigraphy. Clinical Nuclear Medicine 1996 21 11 831 833 2-s2.0-0029903558 10.1097/00003072-199611000-00001 (Pubitemid 26374960)
14. Wiesner W., Engel H., von Schulthess G. K., Krestin G. P., Bicik I., FDG PET-negative liver metastases of a malignant melanoma and FDG PET-positive Hurthle cell tumor of the thyroid. European Radiology 1999 9 5 975 978 2-s2.0-0032604633 10.1007/s003300050779
15. Lang B. H., The role of 18F-fluorodeoxyglucose positron emission tomography in the prognostication, diagnosis, and management of thyroid carcinoma. Journal of Thyroid Research 2012 2012 8 198313 10.1155/2012/198313
16. Pryma D. A., Schöder H., Gönen M., Robbins R. J., Larson S. M., Yeung H. W. D., Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. Journal of Nuclear Medicine 2006 47 8 1260 1266 2-s2.0-33749046302 (Pubitemid 47544877)
17. Lowe V. J., Mullan B. P., Hay I. D., McIver B., Kasperbauer J. L., 18F-FDG PET of patients with Hürthle cell carcinoma. Journal of Nuclear Medicine 2003 44 9 1402 1406 (Pubitemid 39663351)
18. Plotkin M., Hautzel H., Krause B. J., Müller-Gärtner H. W., Schmidt D., Larisch R., Mottaghy F. M., Boerner A. R., Herzog H., Vosberg H., Implication of 2-18fluor-2-deoxyglucose positron emission tomography in the follow-up of Hürthle cell thyroid cancer. Thyroid 2002 12 2 155 161 2-s2.0-0036009138 (Pubitemid 34214000)
19. Poisson T., Deandreis D., Leboulleux S., Bidault F., Bonniaud G., Baillot S., Aupérin A., Al Ghuzlan A., Travagli J. P., Lumbroso J., Baudin E., Schlumberger M., 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 12 2277 2285 2-s2.0-78649777095 10.1007/s00259-010-1570-6
20. Bogsrud T. V., Karantanis D., Nathan M. A., Mullan B. P., Wiseman G. A., Kasperbauer J. L., Reading C. C., Hay I. D., Lowe V. J., 18F-FDG PET in the management of patients with anaplastic thyroid carcinoma. Thyroid 2008 18 7 713 719 2-s2.0-47549092154 10.1089/thy.2007.0350 (Pubitemid 352009926)
21. Are C., Shaha A. R., Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Annals of Surgical Oncology 2006 13 4 453 464 2-s2.0-33644977631 10.1245/ASO.2006.05.042
22. Chiacchio S., Lorenzoni A., Boni G., Rubello D., Elisei R., Mariani G., Anaplastic thyroid cancer: prevalence, diagnosis and treatment. Minerva Endocrinologica 2008 33 4 341 357 2-s2.0-60849091644
23. McIver B., Hay I. D., Giuffrida D. F., Dvorak C. E., Grant C. S., Thompson G. B., van Heerden J. A., Goellner J. R., Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001 130 6 1028 1034 2-s2.0-0035666788 10.1067/msy.2001.118266 (Pubitemid 34014569)
24. Khan N., Oriuchi N., Higuchi T., Endo K., Review of fluorine-18-2-fluoro- 2-deoxy-d-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas. Cancer Control 2005 12 4 254 260 2-s2.0-27644511254 (Pubitemid 41552318)
25. Mosci C., Iagaru A., PET/CT imaging of thyroid cancer. Clinical Nuclear Medicine 2011 36 12 e180 e185 10.1097/RLU.0b013e3182291d03
26. Nikiforov Y. E., Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocrine Pathology 2004 15 4 319 327 2-s2.0-13444311710 10.1385/EP:15:4:319 (Pubitemid 40208912)
27. Garcia-Rostan G., Zhao H., Camp R. L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M. L., Costa J., Tallini G., ras Mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal of Clinical Oncology 2003 21 17 3226 3235 2-s2.0-0141465066 10.1200/JCO.2003.10.130 (Pubitemid 46606254)
28. Volante M., Rapa I., Gandhi M., Bussolati G., Giachino D., Papotti M., Nikiforov Y. E., RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. Journal of Clinical Endocrinology and Metabolism 2009 94 12 4735 4741 2-s2.0-73249128877 10.1210/jc.2009-1233
29. Ma W. W., Jacene H., Song D., Vilardell F., Messersmith W. A., Laheru D., Wahl R., Endres C., Jimeno A., Pomper M. G., Hidalgo M., [18F] fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. Journal of Clinical Oncology 2009 27 16 2697 2704 2-s2.0-66849095262 10.1200/JCO.2008.18.8383
30. Rivera M., Ghossein R. A., Schoder H., Gomez D., Larson S. M., Tuttle R. M., Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma. Cancer 2008 113 1 48 56 2-s2.0-47149102563 10.1002/cncr.23515 (Pubitemid 351976385)
31. Kim C. H., Yoo I. R., Chung Y. A., Park Y. H., Kim S. H., Sohn H. S., Chung S. K., Influence of thyroid-Stimulating hormone on 18F-fluorodeoxyglucose and 99mTc-methoxyisobutylisonitrile uptake in human poorly differentiated thyroid cancer cells in vitro. Annals of Nuclear Medicine 2009 23 2 131 136 2-s2.0-65349126419 10.1007/s12149-008-0218-0
32. Ghossein R., Livolsi V. A., Papillary thyroid carcinoma tall cell variant. Thyroid 2008 18 11 1179 1181 2-s2.0-56549084556 10.1089/thy.2008.0164
33. Kuo C. S., Tang K. T., Lin J. D., Yang A. H., Lee C. H., Lin H. D., Diffuse sclerosing variant of papillary thyroid carcinoma with multiple metastases and elevated serum carcinoembryonic antigen level. Thyroid 2012 22 11 1187 1190 10.1089/thy.2011.0361
34. Xu Y. H., Song H. J., Qiu Z. L., Luo Q. Y., Extensive lymph node metastases found by (18)F-FDG-PET/CT in a patient with diffuse sclerosing variant of papillary thyroid carcinoma. Hellenic Journal of Nuclear Medicine 2011 14 2 188 189 2-s2.0-79961161149
35. Wong T. Z., Jain M. K., Spratt S. E., I-131, I-123, and F-18 FDG-PET imaging in a patient with diffuse sclerosing variant of papillary thyroid cancer. Clinical Nuclear Medicine 2008 33 12 834 837 2-s2.0-58749088411 10.1097/RLU.0b013e31818bf135
36. Giovanella L., Fasolini F., Suriano S., Mazzucchelli L., Hyperfunctioning solid/trabecular follicular carcinoma of the thyroid gland. Journal of Oncology 2010 2010 4 2-s2.0-77956807538 10.1155/2010/635984 635984
37. Diehl M., Graichen S., Menzel C., Lindhorst E., Grünwald F., F-18 FDG PET in insular thyroid cancer. Clinical Nuclear Medicine 2003 28 9 728 731 2-s2.0-1542347158 10.1097/01.rlu.0000082658.78218.0f (Pubitemid 38295196)
38. Deandreis D., Al Ghuzlan A., Leboulleux S., Lacroix L., Garsi J. P., Talbot M., Lumbroso J., Baudin E., Caillou B., Bidart J. M., Schlumberger M., Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocrine-Related Cancer 2011 18 1 159 169 2-s2.0-79251484686 10.1677/ERC-10-0233